Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study
By F. Zhou, Ting Yu, R. Du, Guohui Fan, Y. Liu, Zhi-bo Liu, J. Xiang, Ye-ming Wang, Bin Song, Xiaoying Gu and 9 more. The Lancet, 2020
23,319 citations recorded by the source corpus.
Background Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described. Methods In this retrospective, multicentre cohort study, we included all adult inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020. Demographic, clinical, treatment, and laboratory data, including serial samples for viral RNA detection, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Findings 191 patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital. 91 (48%) patients had a comorbidity, with hypertension being the most common (58 [30%] patients), followed by diabetes (36 [19%] patients) and coronary heart disease (15 [8%] patients). Multivariable regression showed increasing odds of in-hospital death associated with older age (odds ratio 1·10, 95% CI 1·03–1·17, per year increase; p=0·0043), higher Sequential Organ Failure Assessment (SOFA) score (5·65, 2·61–12·23; p<0·0001), and d-dimer greater than 1 μg/mL (18·42, 2·64–128·55; p=0·0033) on admission. Median duration of viral shedding was 20·0 days (IQR 17·0–24·0) in survivors, but SARS-CoV-2 was detectable until death in non-survivors. The longest observed duration of viral shedding in survivors was 37 days. Interpretation The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future. Funding Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences; National Science Grant for Distinguished Young Scholars; National Key Research and Development Program of China; The Beijing Science and Technology Project; and Major Projects of National Science and Technology on New Drug Creation and Development.
Subfields: Infectious Diseases, Neurology, Oncology
View Paper: https://www.semanticscholar.org/paper/5f0ada90bf4546f0ec4d79de05d28f28ee95f318
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
- M. Bansal
- Kwok-Yung Yuen
- Kwok-Hung Chan
- T. Hirano
- Şükriye Bayrak Özdin
- Selçuk Özdin
- Richard C. Becker
In Neurology
- M. Cushman
- P. Calder
- T. Hirano
- Şükriye Bayrak Özdin
- Selçuk Özdin
- Richard C. Becker
- David B. Graves
- M. Bansal
In Oncology
- Matthew D. Hall
- P. Calder
- Andrea L. Bertozzi
- T. Hirano
- Xiaochun Ma
- Şükriye Bayrak Özdin
- Xu Li
- Selçuk Özdin
Citations in the corpus
- SARS-CoV-2 and viral sepsis: observations and hypotheses (2020, background): “4 However, the concrete mechanisms for coagulopathy are not identified yet.”
- Urban Density and Covid-19 (2020, background): “First, access to primary healthcare might affect the presence and management of underlying health conditions which consider being risk factors for COVID-19 mortality (Zhou et al., 2020). Second, access might also affect the probability of seeking and receiving medical treatment once infected with CO”
- Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study (2020, background): “For instance, in a retrospective study from Wuhan, diabetes was present in 19% of 191 COVID-19 inpatients but its prevalence raised to 31% in deceased people compared with 14% in those who survived [12].”
- On the Alert for Cytokine Storm: Immunopathology in COVID‐19 (2020, background): “Sepsis, respiratory failure, and acute respiratory distress syndrome (ARDS) are common complications of the disease (1).”
- Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis (2020, background): “Finally, a total of 13 studies with 3027 patients were included [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] ( Figure 1 ).All of the selected studies were published in 2020 with different sample patient sizes that ranged from 27 to 1099 patients.”
- Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial (2020, background): “The clinical studies of some drugs (human interferon alfa-2b, ribavirin, chloroquine phosphate, lopinavir and arbidol) were currently undergoing to test the efficacy and safety of these drugs in the treatment of COVID-19 [7].”
- Rapid implementation of mobile technology for real-time epidemiology of COVID-19 (2020, background): “incidence and outcomes vary according to age, sex, race/ethnicity, and underlying health status, with inconsistent evidence suggesting that commonly used medications such as angiotensin-converting enzyme (ACE) inhibitors, thiazolidinediones (TZD), and ibuprofen may alter the natural disease course (”
- Elevated Glucose Levels Favor SARS-CoV-2 Infection and Monocyte Response through a HIF-1α/Glycolysis-Dependent Axis (2020, neutral): “diseases, and diabetes are among the main risk factors for severe COVID-19 symptoms (Guo et al., 2020; Jordan et al., 2020; Zhou et al., 2020; Zhu et al., 2020).”
- The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease (2020, background): “Although inflammation is more lung centered, than multi-organ, the argument for IL-6 involvement in COVID-19 related MAS comes from biochemical parameters changes including ferritin and the preliminary open reports of anti-IL6R efficacy [28,50].”
- Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study (2020, background): “[3] [4] [5] [6] Although the clinical spectrum of severe COVID-19 has been characterized in reports from China and Italy, [3] [4] [5] [6] [7] [8] understanding of COVID-19-related critical illness in the U.S. has been limited to small caseseries from Washington state.”
- Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System (2020, background): “30, 86 Lipopolysaccharide-induced acute lung injury decreased expression of ACE2, precipitated inflammatory injury, and upregulated expression of renin, Ang II, ACE, and AT1 receptors.”
- Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. (2020, neutral): “Hypertension 509 (49) 0 4 (11) 21 (26) 121 (44) 195 (51) 156 (62) 12 (75) 0”
- Mortality-related risk factors of COVID-19: a systematic review and meta-analysis of 42 studies and 423,117 patients (2021, background): “In addition a study in China [17] have shown that rising D-dimer levels during the course of hospitalization are associated with the worst long-term outcomes.”
- Autopsy Findings and Venous Thromboembolism in Patients With COVID-19 (2020, background): “Other researchers have described coagulopathy as a common complication in patients with severe COVID-19 (5, 6, 19).”